Healthcare | Testing for disease
A modern healthcare system should invest in diagnostics and testing
March 5, 2021
Thierry Bernard, CEO of QIAGEN, says the COVID-19 pandemic might yet have an upside: more prevention-driven healthcare.
COVID-19 quickly saw the testing industry step up to the incredible challenge of increasing output […] – many thousands more devices that can now be used to fight other infectious diseases and cancers better and quicker.
Modern testing has traditionally been undervalued and underestimated. While 66 percent of treatment decision-making was based on so-called in-vitro diagnostics, only 2.3 percent of US healthcare expenditure went into buying these regulated testing devices.
Testing has moved out of the laboratory to the patient’s bedside – with compact portable instruments that sit in a hospital ward or doctor’s office. And getting samples has become less invasive.